- MediPharm Labs (MEDIF, Financial) refutes allegations made by shareholder Apollo Technology Capital Corporation.
- Company received a clean audit opinion from MNP LLP dated March 30, 2025.
- MediPharm has initiated legal proceedings against Apollo to address false claims and seek court costs.
MediPharm Labs Corp. (MEDIF) has responded to recent allegations made by Apollo Technology Capital Corporation, characterizing them as "baseless allegations of malfeasance" and part of a misinformation campaign. Apollo owns a 3% stake in MediPharm and is reportedly attempting to gain control of the company's Board of Directors.
Despite these claims, MediPharm emphasizes its transparency and compliance, pointing to a clean audit opinion for the fiscal year 2025 from MNP LLP, dated March 30, 2025. This audit preserves the company's consistent record of clean financial audits since going public.
To counter Apollo's allegations, MediPharm has commenced legal proceedings to address what it describes as material misstatements made by the shareholder. The company is also seeking court costs from these legal actions.
MediPharm Labs continues its operations within the regulatory compliance framework across various international jurisdictions, supplying cannabis and advanced cannabinoid-based products to both domestic and international markets.
